Tiziana Life Science reports Independent Third Party Article in New England Journal of Medicine on Intravenous Treatment with a Humanized AntiCD3 mAb showing delays in progression of Type 1 Diabetes

Independent third party Phase 2 results show Teplizumab a mouse derived humanized antiCD3 monoclonal antibody mAb significantly slowed progression of Type 1 diabetes in high risk population Tiziana Life Sciences plc Nasdaq TLSA AIM TILS Tiziana or the Comp...